Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1734-1740

  Kong, Dexin ^a   Yamori, Takao ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PX 866; S6 KINASE; SF 1126; TG 100 115; VASCULOTROPIN; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CHROMOSOME 10; CHROMOSOME DELETION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMONES; COMBINED MODALITY THERAPY; HUMANS; MORPHOLINES; NEOPLASMS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS;

EID: 50149101312     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00891.x     Document Type: Review

References (97)

1. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387: 673-6.
2. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem Sci 1997; 22: 267-72.
3. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988; 332: 644-6.
4. Franke TF, Kaplan DR, Cantley LC. PI3K: Downstream AKTion blocks apoptosis. Cell 1997; 88: 435-7.
5. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem J 1998; 333: 471-90.
6. Anderson KE, Jackson SP. Class I phosphoinositide 3-kinases. Int J Biochem Cell Biol 2003; 35: 1028-33.
7. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through class I PI3K in mammalian cells. Biochem Soc Trans 2006; 34: 647-62.
8. 3K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
9. Stein RC, Waterfield MD. PI3-kinase inhibition: A target for drug development? Mol Med Today 2000; 6: 347-57.
10. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
11. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998; 1436: 127-50.
12. Vanhaesebroeck B, Leevers SJ, Ahmadi K et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602.
13. Murray JT, Panaretou C, Stenmark H, Miaczynska M, Backer JM. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. Traffic 2002; 3: 416-27.
14. Christoforidis S, Miaczynska M, Ashman K et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat Cell Biol 1999; 1: 249-52.
15. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
16. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194-204.
17. Chantry D, Vojtek A, Kashishian A et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272: 19.236-41.
18. Vanhaesebroeck B, Welham MJ, Kotani K et al. P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 4330-5.
19. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
20. Levine DA, Bogomolniy F, Yee CJ et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11: 2875-8.
21. Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006; 340: 469-75.
22. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006; 125: 733-47.
23. Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.
24. Hirsch E, Katanaev VL, Garlanda C et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-53.
25. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 2000; 287: 1046-9.
26. Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-6.
27. Barber DF, Bartolome A, Hernandez C et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-5.
28. Camps M, Ruckle T, Ji H et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43.
29. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003; 170: 2647-54.
30. Wendel HG, De Stanchina E, Fridman JS et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7.
31. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005; 5: 653-61.
32. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 279: 45.643-51.
33. Harrington LS, Findlay GM, Gray A et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166: 213-23.
34. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-83.
35. Vogt PK, Kang S. Kinase inhibitors: Vice becomes virtue. Cancer Cell 2006; 9: 327-8.
36. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-8.
37. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999; 402: 313-20.
38. Walker EH, Pacold ME, Perisic O et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-19.
39. Levy J, Teuerstein I, Marbach M, Radian S, Sharoni Y. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: Inhibition by quercetin. Biochem Biophys Res Commun 1984; 123: 1227-33.
40. Srivastava AK. Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem Biophys Res Commun 1985; 131: 1-5.
41. Gschwendt M, Horn F, Kittstein W, Marks F. Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem Biophys Res Commun 1983; 117: 444-7.
42. Cochet C, Feige JJ, Pirollet F, Keramidas M, Chambaz EM. Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. Biochem Pharmacol 1982; 31: 1357-61.
43. Graziani Y, Erikson E, Erikson RL. The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in.vitro and in.vivo. Eur J Biochem 1983; 135: 583-9.
44. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-8.
45. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
46. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In.vivo and in.vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-6.
47. Brian PWCP, Hemming HG, Norris GLF. Wortmannin, an antibiotic produced by penicillium wortmanni. Trans Br Mycol Soc 1957; 40: 365-8.
48. Petcher TJWH, Kis Z. Crystal structure and absolute configuration of wortmannin and of wortmannin p-bromobenzoate. J Chem Soc Chem Commun 1972:1061-2.
49. Wiesinger D, Gubler HU, Haefliger W, Hauser D. Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives. Experientia 1974; 30: 135-6.
50. Powis G, Bonjouklian R, Berggren MM et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994; 54: 2419-23.
51. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem 1994; 269: 3563-7.
52. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993; 296: 297-301.
53. Nakanishi S, Kakita S, Takahashi I et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 1992; 267: 2157-63.
54. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16: 1722-33.
55. Ihle NT, Williams R, Chow S et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-72.
56. Ihle NT, Paine-Murrieta G, Berggren MI et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-57.
57. Puri KD, Doggett TA, Douangpanya J et al. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 2004; 103: 3448-56.
58. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006; 20: 455-65.
59. Sujobert P, Bardet V, Cornillet-Lefebvre P et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063-6.
60. Billottet C, Grandage VL, Gale RE et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25: 6648-59.
61. Doukas J, Wrasidlo W, Noronha G et al. Phosphoinositide 3-kinase gamma/ delta inhibition limits infarct size after myocardial ischemia/ reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19.866-71.
62. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-9.
63. Fan QW, Cheng CK, Nicolaides TP et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67: 7960-5.
64. Raynaud FI, Eccles S, Clarke PA et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67: 5840-50.
65. Stauffer FG-EC, Furet P, Schnell C, Ruetz S, Michel M, Fritsch CM. Biochemical, cellular and in.vivo profiling of a new PI3K inhibitor from the imidazoquinoline series. In:
66. Wahl GM, Depinho RA, eds. Proceedings of American Association for Cancer Research. 14-18 April, 2007, Los Angeles, USA, 2007. Columbia, USA: Cadmus; 66.
67. Garlich JR, De P, Dey N et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68: 206-15.
68. Yaguchi S, Fukui Y, Koshimizu I et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-56.
69. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 2007; 98: 1638-42.
70. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
71. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J Cell Physiol 2006; 209: 56-66.
72. Wen S, Stolarov J, Myers MP et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001; 98: 4622-7.
73. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 2002; 277: 10.760-6.
74. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-56.
75. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
76. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363-9.
77. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
78. Kitamura T, Asai N, Enomoto A et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol 2008; 10: 329-37.
79. Enomoto A, Murakami H, Asai N et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell 2005; 9: 389-402.
80. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97: 1749-53.
81. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007; 19: 2487-97.
82. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003; 63: 3585-92.
83. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in.vitro and in.vivo ovarian cancer models. Cancer Res 2002; 62: 1087-92.
84. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-8.
85. Skorski T, Kanakaraj P, Nieborowska-Skorska M et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-36.
86. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-80.
87. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868-76.
88. Weisberg E, Banerji L, Wright RD et al. Potentiation of anti-leukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: Effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008; 111: 3723-334.
89. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006; 32: 74-89.
90. Mueller W, Mizoguchi M, Silen E, D'Amore K, Nutt CL, Louis DN. Mutations of the PIK3CA gene are rare in human glioblastoma. Acta Neuropathol 2005; 109: 654-5.
91. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA. Combinatorial efficacy achieved through two-point blockade within a signaling pathway.-.a chemical genetic approach. Cancer Res 2003; 63: 8930-8.
92. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998; 58: 4375-82.
93. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G 2-M delay. Clin Cancer Res 1997; 3: 1149-56.
94. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110β-γ, and -δ isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2006; 103: 1289-94.
95. Poh TW, Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 2005; 65: 6264-74.
96. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003-6.
97. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: Size matters. Oncogene 2003; 22: 8983-98.